Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. (2013)

First Author: Babiker AG
Attributed to:  MRC Clinical Trials Unit as the London Hub for Trials Methodology Research funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1177/1740774512440342

PubMed Identifier: 22547421

Publication URI: http://europepmc.org/abstract/MED/22547421

Type: Journal Article/Review

Volume: 10

Parent Publication: Clinical trials (London, England)

Issue: 1 Suppl

ISSN: 1740-7745